Company News
05/18/2021
ReAlta Life Sciences Expands Phase 1 Clinical Trial of RLS-0071
ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening diseases through harnessing the power of the immune system, today announced that it has received a no objection letter (NOL) from Health Canada to an Amendment of the Company’s Phase 1 clinical trial of RLS-0071 in healthy volunteers. The study design has been modified to add …
05/18/2021
Children’s National spinout AlgometRx developed a device that measures pain
A longtime pediatric anesthesiologist at Children’s National Hospital, Dr. Julia Finkel has long wanted a more objective way to measure how much pain patients are feeling. “For pain, we do it very empirically,” Dr. Finkel said. “The patient says they hurt, we give them a drug. They either feel better or they don’t…It’s done in …
05/17/2021
Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement
Landos Biopharma, Inc, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, and LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 …
05/10/2021
Landos Biopharma Announces First Patient Dosed in a Phase 2 Study of Omilancor for Crohn’s Disease
Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, announced that the Company has dosed the first patient in a Phase 2 study of omilancor, Landos’ novel, orally administered, gut-restricted LANCL2 agonist, for the treatment of moderate-to-severe Crohn’s disease (CD). “We are extremely proud of …
05/07/2021
BIO-CAT Grows in Zion Crossroads
BIO-CAT, Inc., a biotechnology company that specializes in enzymes and other advanced microbial solutions, plans to add at least 30,000 square feet to its fermentation facilities in Zion Crossroads. The expansion is projected to start in 2022. The company will add several new jobs and is considering building another 30,000-square-foot section in a second phase. …